Jeffrey S. Glenn, MD, Phd.

Co-founder of Riboscience and serves as a Senior Advisor for virology and strategy.

He is also an Associate Professor of Medicine and Microbiology & Immunology at Stanford University School of Medicine, and Director of the Center for Hepatitis and Liver Tissue Engineering. His primary research is molecular virology and novel antiviral therapies. He is the principal investigator on multiple NIH grants, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee. He is the founder of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR).